Abstract
INTRODUCTION: aim is outcome of 11C-Choline-PET guided SBRT on lymph node metastases.
MATERIALS AND METHODS: patients with 1 - 4 lymph node metastases detected by 11C-choline-PET were treated with SBRT. Toxicity, treated metastases control and Progression Free Survival were computed.
RESULTS: twenty-six patients, 38 lymph node metastases were irradiated. No grade ≥ 2 toxicity. Median PSA-nadir after RT was 1.02 ng/mL. Post-treatment 11C-Choline-PET showed metabolic complete response in 17 metastases (44,7%), partial response in 9 metastases (38%).
CONCLUSION: SBRT is effective and safe for lymph node metastases. PET is important in identification of gross tumor and evaluation of the response.
| Original language | English |
|---|---|
| Pages (from-to) | 586-593 |
| Number of pages | 8 |
| Journal | Cancer Investigation |
| Volume | 35 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Oct 21 2017 |
Fingerprint
Keywords
- Aged
- Carbon Radioisotopes
- Choline
- Disease-Free Survival
- Humans
- Kallikreins
- Kaplan-Meier Estimate
- Lymph Nodes
- Lymphatic Metastasis
- Male
- Positron Emission Tomography Computed Tomography
- Predictive Value of Tests
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Radiopharmaceuticals
- Radiosurgery
- Retrospective Studies
- Time Factors
- Treatment Outcome
- Journal Article
Cite this
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. / Franzese, Ciro; Lopci, Egesta; Di Brina, Lucia; D'Agostino, Giuseppe Roberto; Navarria, Pierina; Mancosu, Pietro; Tomatis, Stefano; Chiti, Arturo; Scorsetti, Marta.
In: Cancer Investigation, Vol. 35, No. 9, 21.10.2017, p. 586-593.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer
AU - Franzese, Ciro
AU - Lopci, Egesta
AU - Di Brina, Lucia
AU - D'Agostino, Giuseppe Roberto
AU - Navarria, Pierina
AU - Mancosu, Pietro
AU - Tomatis, Stefano
AU - Chiti, Arturo
AU - Scorsetti, Marta
PY - 2017/10/21
Y1 - 2017/10/21
N2 - INTRODUCTION: aim is outcome of 11C-Choline-PET guided SBRT on lymph node metastases.MATERIALS AND METHODS: patients with 1 - 4 lymph node metastases detected by 11C-choline-PET were treated with SBRT. Toxicity, treated metastases control and Progression Free Survival were computed.RESULTS: twenty-six patients, 38 lymph node metastases were irradiated. No grade ≥ 2 toxicity. Median PSA-nadir after RT was 1.02 ng/mL. Post-treatment 11C-Choline-PET showed metabolic complete response in 17 metastases (44,7%), partial response in 9 metastases (38%).CONCLUSION: SBRT is effective and safe for lymph node metastases. PET is important in identification of gross tumor and evaluation of the response.
AB - INTRODUCTION: aim is outcome of 11C-Choline-PET guided SBRT on lymph node metastases.MATERIALS AND METHODS: patients with 1 - 4 lymph node metastases detected by 11C-choline-PET were treated with SBRT. Toxicity, treated metastases control and Progression Free Survival were computed.RESULTS: twenty-six patients, 38 lymph node metastases were irradiated. No grade ≥ 2 toxicity. Median PSA-nadir after RT was 1.02 ng/mL. Post-treatment 11C-Choline-PET showed metabolic complete response in 17 metastases (44,7%), partial response in 9 metastases (38%).CONCLUSION: SBRT is effective and safe for lymph node metastases. PET is important in identification of gross tumor and evaluation of the response.
KW - Aged
KW - Carbon Radioisotopes
KW - Choline
KW - Disease-Free Survival
KW - Humans
KW - Kallikreins
KW - Kaplan-Meier Estimate
KW - Lymph Nodes
KW - Lymphatic Metastasis
KW - Male
KW - Positron Emission Tomography Computed Tomography
KW - Predictive Value of Tests
KW - Prostate-Specific Antigen
KW - Prostatic Neoplasms
KW - Radiopharmaceuticals
KW - Radiosurgery
KW - Retrospective Studies
KW - Time Factors
KW - Treatment Outcome
KW - Journal Article
U2 - 10.1080/07357907.2017.1375116
DO - 10.1080/07357907.2017.1375116
M3 - Article
C2 - 28980836
VL - 35
SP - 586
EP - 593
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 9
ER -